公开(公告)号：WO2016140921A1

公开(公告)日：2016-09-09

申请号：PCT/US2016/020101

申请日：2016-02-29

Applicant: 180 THERAPEUTICS LP ,  LARSEN, Glenn ,  NANCHAHAL, Jagdeep ,  FELDMANN, Marc

Inventor： LARSEN, Glenn ,  NANCHAHAL, Jagdeep ,  FELDMANN, Marc

IPC: C07K16/28

CPC classification number: A61K39/395 ,  A61K9/00 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/00 ,  A61K31/713 ,  A61K38/193 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61P43/00 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/35

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.

Abstract translation: 本发明提供了治疗患有局部纤维化病症的患者的方法，其包括向患者施用一定量的有效治疗患者的IL-33拮抗剂。 本发明还提供了治疗患有局部纤维化病症的患者的方法，其包括向患者施用一定量的有效治疗患者的TNF受体2（TNFR2）拮抗剂。

公开(公告)号：WO2008060626A9

公开(公告)日：2008-07-31

申请号：PCT/US2007024100

申请日：2007-11-15

Applicant: HYDRA BIOSCIENCES INC ,  CHONG JAYHONG A ,  FANGER CHRISTOPHER ,  LARSEN GLENN R ,  LUMMA WILLIAM C JR ,  MAHADEVAN ANU ,  MELTZER PETER ,  MORAN MAGDALENE M ,  RIPKA AMY ,  UNDERWOOD DENNIS JOHN ,  WEIGELE MANFRED ,  ZHEN XIAOGUANG

Inventor： CHONG JAYHONG A ,  FANGER CHRISTOPHER ,  LARSEN GLENN R ,  LUMMA WILLIAM C JR ,  MAHADEVAN ANU ,  MELTZER PETER ,  MORAN MAGDALENE M ,  RIPKA AMY ,  UNDERWOOD DENNIS JOHN ,  WEIGELE MANFRED ,  ZHEN XIAOGUANG

IPC: C07D417/12 ,  A61K31/428 ,  A61K31/4709 ,  A61P29/00

CPC classification number: C07D513/04 ,  A61K8/49 ,  A61K8/4906 ,  A61K8/4926 ,  A61K31/428 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/538 ,  A61K31/55 ,  A61Q7/02 ,  C07D215/08 ,  C07D223/16 ,  C07D277/70 ,  C07D401/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12

Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRP V3.

Abstract translation: 本申请涉及用于治疗与TRP V3相关的疼痛和其它病症的化合物和方法。

公开(公告)号：WO2005118782A3

公开(公告)日：2006-06-29

申请号：PCT/US2005013259

申请日：2005-04-18

Applicant: HYDRA BIOSCIENCES INC ,  LARSEN GLENN ,  MARVIN MARTHA ,  LI DEAN Y ,  WANG ELIZABETH ,  CHEN C M AMY ,  SHAMAH STEVEN M

Inventor： LARSEN GLENN ,  MARVIN MARTHA ,  LI DEAN Y ,  WANG ELIZABETH ,  CHEN C M AMY ,  SHAMAH STEVEN M

IPC: C12N5/06 ,  A61K38/00 ,  A61K38/17 ,  A61K38/18 ,  A61K47/48 ,  A61P9/10 ,  C07K14/475 ,  C12N5/08

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K47/60

Abstract: The present invention provides novel methods and compositions for promoting proliferation and/or regeneration of neonatal or adult cardiac cells comprising contacting the cells with a Wnt-related polypeptide. Also disclosed are convalently modified Wnt-polypeptides comprising a PEG containing moiety.

Abstract translation: 本发明提供用于促进新生儿或成人心脏细胞增殖和/或再生的新方法和组合物，包括使细胞与Wnt相关多肽接触。 还公开了包含含PEG部分的共价修饰的Wnt-多肽。

公开(公告)号：WO2005118782A2

公开(公告)日：2005-12-15

申请号：PCT/US2005/013259

申请日：2005-04-18

Applicant: HYDRA BIOSCIENCES, INC. ,  LARSEN, Glenn ,  MARVIN, Martha ,  LI, Dean, Y. ,  WANG, Elizabeth ,  CHEN, C., M., Amy ,  SHAMAH, Steven, M.

Inventor： LARSEN, Glenn ,  MARVIN, Martha ,  LI, Dean, Y. ,  WANG, Elizabeth ,  CHEN, C., M., Amy ,  SHAMAH, Steven, M.

IPC: C12N5/06

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K47/60

Abstract: The present invention provides novel methods and compositions for promoting proliferation and/or regeneration.

Abstract translation: 本发明提供用于促进增殖和/或再生的新方法和组合物。

公开(公告)号：WO2004016229A2

公开(公告)日：2004-02-26

申请号：PCT/US2003/025996

申请日：2003-08-18

Applicant: WYETH ,  PITTMAN, Debra, D. ,  CLANCY, Brian ,  LARSEN, Glenn ,  TREPICCHIO, William, L. ,  BRENNAN, Fionula, Mary ,  FELDMANN, Marc ,  FOXWELL, Brian, John, Maurice ,  FELDMAN, Jeffrey, L.

Inventor： PITTMAN, Debra, D. ,  CLANCY, Brian ,  LARSEN, Glenn ,  TREPICCHIO, William, L. ,  BRENNAN, Fionula, Mary ,  FELDMANN, Marc ,  FOXWELL, Brian, John, Maurice ,  FELDMAN, Jeffrey, L.

IPC: A61K

CPC classification number: C07K14/70503 ,  C07K2319/30 ,  C07K2319/70

Abstract: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.

Abstract translation: 公开了包含高级糖基末端产物配体结合元件（RAGE-LBE）的受体和免疫球蛋白元件的融合蛋白。 还公开了包含RAGE-LBE和二聚化结构域的融合蛋白。 还公开了编码这种融合蛋白的核酸和使用公开的核酸和蛋白质例如治疗RAGE相关病症的方法。 还公开了另外的组合物和方法。

公开(公告)号：WO2003028630A3

公开(公告)日：2003-04-10

申请号：PCT/US2002/029839

申请日：2002-10-04

Applicant: GENETICS INSTITUTE LLC. ,  CARTER, Laura ,  WHITTERS, Matthew, J. ,  COLLINS, Mary ,  YOUNG, Deborah, A. ,  LARSEN, Glenn ,  DONALDSON, Debra, D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

Inventor： CARTER, Laura ,  WHITTERS, Matthew, J. ,  COLLINS, Mary ,  YOUNG, Deborah, A. ,  LARSEN, Glenn ,  DONALDSON, Debra, D. ,  LOWE, Leslie, D. ,  DUNUSSI, Kyri ,  MA, Margery ,  WITEK, JoAnn, S. ,  KASAIAN, Marion, T. ,  UNGAR, Michelle ,  CARRENO, Beatriz

IPC: A61K38/00

Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo , e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo , e.g., for example, for use in treating cancer and infectious disorders.

公开(公告)号：WO1993005803A1

公开(公告)日：1993-04-01

申请号：PCT/US1992008208

申请日：1992-09-25

Applicant: GENETICS INSTITUTE, INC. ,  AHERN, Timothy, J. ,  CUMMING, Dale, A. ,  LARSEN, Glenn, R. ,  SULLIVAN, Francis, X.

Inventor： GENETICS INSTITUTE, INC.

IPC: A61K37/02

CPC classification number: A61K31/70 ,  A61K31/715 ,  A61K38/00 ,  C07K14/765

Abstract: The use of pharmaceutical compositions for the treatment of conditions characterized by selectin-mediated cellular adhesion is disclosed, said compositions comprising an effective amount of an anti-inflammatory glycoconjugate inhibitor of general formula (I), said glycoconjugate being in association with a pharmaceutically acceptable carrier, wherein binding between selectins and their ligands is inhibited. Methods for making such glycoconjugates are also provided.

Abstract translation: 所述组合物包含有效量的通式（I）的抗炎性糖缀合物抑制剂，所述糖缀合物与药学上可接受的载体相结合 其中选择素及其配体之间的结合被抑制。 还提供了制备这种糖缀合物的方法。

公开(公告)号：WO1987004722A1

公开(公告)日：1987-08-13

申请号：PCT/US1987000257

申请日：1987-01-30

Applicant: GENETICS INSTITUTE, INC. ,  LARSEN, Glenn, R. ,  AHERN, Tim, J.

Inventor： GENETICS INSTITUTE, INC.

IPC: C12N15/00

CPC classification number: C12N9/6459 ,  C12Y304/21069

Abstract: Thrombolytic proteins which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.

Abstract translation: 具有组织纤溶酶原型活性的溶血蛋白。 蛋白质的特征在于在94个氨基酸的N末端和/或在Arg-275和/或一个或多个N-连接的糖基化位点处的修饰。 公开了制备这些蛋白质的方法，其含有含有它们的治疗组合物。

公开(公告)号：WO2018045213A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/049696

申请日：2017-08-31

Applicant: 180 THERAPEUTICS LP ,  NANCHAHAL, Jagdeep ,  LARSEN, Glenn, R. ,  FELDMANN, Marc

Inventor： NANCHAHAL, Jagdeep ,  LARSEN, Glenn, R. ,  FELDMANN, Marc

IPC: A61K38/02 ,  A61K39/395 ,  C07K16/24 ,  C07K16/46 ,  C07K14/715

Abstract: The subject invention provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a systetic fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.

Abstract translation: 本发明提供了治疗患有系统性纤维化病症的患者的方法，其包括向患者施用有效治疗患者的量的IL-33拮抗剂。 本发明还提供了治疗患有系统性纤维化病症的患者的方法，其包括向患者施用一定量的双特异性抗体，所述双特异性抗体包含IL-33抗原结合结构域，其（i）结合并抑制IL （ii）与IL-33特异性结合并抑制IL-33与IL-33受体结合的TNF受体结合结构域，以及（i）与TNF受体结合并抑制其活化的TNF抗原结合结构域， 或（ii）与TNF特异性结合并抑制TNF结合TNF受体，其中双特异性抗体有效治疗患者。

公开(公告)号：WO2018045210A1

公开(公告)日：2018-03-08

申请号：PCT/US2017/049691

申请日：2017-08-31

Applicant: 180 THERAPEUTICS LP ,  NANCHAHAL, Jagdeep ,  LARSEN, Glenn, R. ,  FELDMANN, Marc

Inventor： 180 THERAPEUTICS LP ,  NANCHAHAL, Jagdeep ,  LARSEN, Glenn, R. ,  FELDMANN, Marc

IPC: A61K38/02 ,  A61K39/395 ,  C07K16/24 ,  C07K16/46 ,  C07K14/715

Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.

Abstract translation: 本发明提供了治疗患有局部纤维化病症的患者的方法，其包括向患者施用有效治疗患者的量的IL-33拮抗剂。 本发明还提供了治疗患有局部纤维化病症的患者的方法，其包括向患者施用一定量的双特异性抗体，所述双特异性抗体包含IL-33抗原结合结构域，其（i）结合并抑制IL （ii）与IL-33特异性结合并抑制IL-33与IL-33受体结合的TNF受体结合结构域，以及（i）与TNF受体结合并抑制其活化的TNF抗原结合结构域， 或（ii）与TNF特异性结合并抑制TNF结合TNF受体，其中双特异性抗体有效治疗患者。